Brainstorm Cell Therapeutics Files 8-K
Ticker: BCLI · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, regulation-fd
TL;DR
Brainstorm Cell Therapeutics filed an 8-K for financial statements and exhibits.
AI Summary
On October 1, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily serves as a notification of their financial statements and exhibits, along with a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Brainstorm Cell Therapeutics Inc. is providing updated financial statements and exhibits, which is a standard regulatory requirement for public companies.
Risk Assessment
Risk Level: low — This 8-K filing is a routine disclosure of financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- October 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36641 (filing_id) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, along with a Regulation FD disclosure.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is October 1, 2024.
In which state is Brainstorm Cell Therapeutics Inc. incorporated?
Brainstorm Cell Therapeutics Inc. is incorporated in Delaware.
What is the SEC file number for Brainstorm Cell Therapeutics Inc.?
The SEC file number for Brainstorm Cell Therapeutics Inc. is 001-36641.
Does this filing contain specific new financial results or material business updates?
Based on the provided excerpt, this filing primarily serves as a notification of financial statements and exhibits and does not detail specific new financial results or material business updates.
Filing Stats: 578 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-10-01 08:00:27
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
Filing Documents
- tm2425286d1_8k.htm (8-K) — 25KB
- tm2425286d1_ex99-1.htm (EX-99.1) — 39KB
- tm2425286d1_ex99-1img001.jpg (GRAPHIC) — 47KB
- tm2425286d1_ex99-1img002.jpg (GRAPHIC) — 202KB
- tm2425286d1_ex99-1img003.jpg (GRAPHIC) — 91KB
- tm2425286d1_ex99-1img004.jpg (GRAPHIC) — 115KB
- tm2425286d1_ex99-1img005.jpg (GRAPHIC) — 78KB
- tm2425286d1_ex99-1img006.jpg (GRAPHIC) — 121KB
- tm2425286d1_ex99-1img007.jpg (GRAPHIC) — 128KB
- tm2425286d1_ex99-1img008.jpg (GRAPHIC) — 127KB
- tm2425286d1_ex99-1img009.jpg (GRAPHIC) — 50KB
- tm2425286d1_ex99-1img010.jpg (GRAPHIC) — 126KB
- tm2425286d1_ex99-1img011.jpg (GRAPHIC) — 93KB
- tm2425286d1_ex99-1img012.jpg (GRAPHIC) — 119KB
- tm2425286d1_ex99-1img013.jpg (GRAPHIC) — 147KB
- tm2425286d1_ex99-1img014.jpg (GRAPHIC) — 107KB
- tm2425286d1_ex99-1img015.jpg (GRAPHIC) — 159KB
- tm2425286d1_ex99-1img016.jpg (GRAPHIC) — 111KB
- tm2425286d1_ex99-1img017.jpg (GRAPHIC) — 126KB
- tm2425286d1_ex99-1img018.jpg (GRAPHIC) — 136KB
- tm2425286d1_ex99-1img019.jpg (GRAPHIC) — 56KB
- tm2425286d1_ex99-1img020.jpg (GRAPHIC) — 82KB
- tm2425286d1_ex99-1img021.jpg (GRAPHIC) — 107KB
- tm2425286d1_ex99-1img022.jpg (GRAPHIC) — 125KB
- tm2425286d1_ex99-1img023.jpg (GRAPHIC) — 102KB
- tm2425286d1_ex99-1img024.jpg (GRAPHIC) — 55KB
- tm2425286d1_ex99-1img025.jpg (GRAPHIC) — 91KB
- tm2425286d1_ex99-1img026.jpg (GRAPHIC) — 174KB
- tm2425286d1_ex99-1img027.jpg (GRAPHIC) — 120KB
- tm2425286d1_ex99-1img028.jpg (GRAPHIC) — 127KB
- tm2425286d1_ex99-1img029.jpg (GRAPHIC) — 55KB
- 0001104659-24-104667.txt ( ) — 4545KB
- bcli-20241001.xsd (EX-101.SCH) — 3KB
- bcli-20241001_lab.xml (EX-101.LAB) — 33KB
- bcli-20241001_pre.xml (EX-101.PRE) — 22KB
- tm2425286d1_8k_htm.xml (XML) — 4KB
01 Financial Statements and
Item 9.01 Financial Statements and Exhibits. (d): Exhibits: Exhibit No. Description 99.1 Company Presentation. 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: October 1 , 2024 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer